Legal Status Overview
Gray AreaMaine has no statute, administrative rule, or Board of Pharmacy chapter that names peptides such as BPC-157, TB-500, or 'research chemicals' as a distinct regulated category. Instead, peptide products are handled under Maine's general pharmacy, drug-outlet, and compounding law, which incorporates federal standards (USP compounding chapters and the federal FDCA/503A-503B framework administered by FDA). In practice this means an FDA-approved or lawfully compounded peptide dispensed on a valid prescription through a licensed Maine pharmacy is legal, while unapproved 'research use only' peptides sold for human use sit in an unresolved gray zone governed by federal law and general state prohibitions rather than any Maine-specific peptide rule. Recent Maine activity touching peptide-class drugs has concerned GLP-1 insurance coverage and multistate consumer-protection pressure on counterfeit and unapproved compounded weight-loss drugs, not a state ban or state authorization of peptides.
Key Points
- The Maine Board of Pharmacy's rule chapters address compounding only in general terms (for example, licensure of sterile compounding pharmacies and compounding for veterinarian office use) and contain no chapter directed at peptides or 'research chemicals' as a category. [1]
- Maine regulates peptide compounding through generic compounding standards: a non-sterile compounding pharmacy must comply with USP General Chapter <795>, which the Board incorporates by reference, and a sterile compounding pharmacy must be separately licensed under Chapter 37 of the Board's rules. [2]
- The Maine Pharmacy Act's definition of compounding expressly covers preparation of drugs 'for the purpose of, or as an incident to, research, teaching or chemical analysis and not for sale,' which is the closest Maine statutory language to a research-use concept and does not create a consumer 'research chemical' exemption. [3]
- The Board of Pharmacy holds broad statutory authority to make rules concerning the sale and dispensing of medications and drugs and to seize drugs and materials found after hearing to be detrimental to the public health and welfare, which is the enforcement hook that would apply to unapproved peptide products sold through licensed outlets. [4]
- Maine's criminal drug schedules in 17-A M.R.S. §1102 enumerate specific substances and categories (such as nonprescription drugs the Board designates, butyl nitrite, and methamphetamine precursor drugs) and do not list peptides such as BPC-157 or TB-500, so these peptides are not Maine-scheduled controlled substances. [5]
- Recent Maine legislation involving peptide-class drugs concerns payment and access rather than legality: LD 480 in the 2025-2026 session would require MaineCare reimbursement for FDA-approved GLP-1 receptor agonists for obesity, with prescriber and prior-authorization limits. [6]
- Maine's Attorney General joined a February 2025 bipartisan multistate letter urging federal action against sellers of counterfeit, unapproved, and contaminated weight-loss drugs and encouraging FDA partnership with state pharmacy boards on compounded GLP-1 safety. [7]
- No Maine Board of Pharmacy bulletin, guidance document, or published enforcement action specifically naming BPC-157, TB-500, or compounded semaglutide/tirzepatide was located in this research; the points above reflect general Maine pharmacy and compounding law plus federal deference, not a peptide-specific Maine source. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Sources
Last researched: 2026-08-10